The rapid evolution of infectious diseases and the emergence of antimicrobial resistance have underscored the need for diagnostic technologies that offer faster, more accurate, and comprehensive pathogen detection. Traditional diagnostic methods, while reliable, are often limited by lengthy turnaround times, low sensitivity, and narrow pathogen coverage. Recent advancements in molecular diagnostics, genomic sequencing, biosensor technologies, and artificial intelligence (AI)-assisted platforms have transformed the landscape of clinical microbiology. Clinical trials are increasingly focused on validating these next-generation technologies to ensure their diagnostic accuracy, clinical utility, and scalability. Tools such as CRISPR-based assays, metagenomic sequencing, and lab-on-a-chip systems are demonstrating unprecedented sensitivity and speed, facilitating early detection and targeted therapy. Moreover, the integration of digital health analytics and AI-driven interpretation promises a paradigm shift toward precision diagnostics. This review highlights key technologies under clinical evaluation, their comparative performance, and the challenges in translating innovation into routine clinical practice. It concludes with perspectives on the future of diagnostic medicine, emphasizing the need for interdisciplinary collaboration, robust regulatory frameworks, and equitable global access to advanced diagnostic solutions.
Dhavalkumar Gohel* (Sun,) studied this question.